Sage Journals: Discover world-class research

Abstract

Background:

Sphingolipids are myelin components and inflammatory signaling intermediates. Sphingolipid metabolism may be altered in people with multiple sclerosis (PwMS), but existing studies are limited by small sample sizes.

Objectives:

To compare the levels of serum ceramides between PwMS and healthy controls (HCs) and to determine whether ceramide levels correlate with disability status, as well as optical coherence tomography (OCT)-derived rates of retinal layer atrophy.

Methods:

We performed targeted lipidomics analyses for 45 ceramides in PwMS (n = 251) and HCs (n = 68). For a subset of PwMS, baseline and 5-year Expanded Disability Status Scale (EDSS) assessments (n = 185), or baseline and serial spectral-domain OCT (n = 180) were assessed.

Results:

Several ceramides, including hexosylceramides, lactosylceramides, and dihydroceramides, were altered in PwMS compared with HCs. Higher levels of Cer16:0 were associated with higher odds of EDSS worsening at 5 years in univariable (odds ratio (OR) = 3.84, 95% confidence interval (CI) = 1.41–10.43) and multivariable analyses accounting for age, sex, and race (OR = 2.97, 95% CI = 1.03–8.59). Each 1 ng/mL higher concentration of Hex-Cer22:0 and DH-HexCer22:0 was associated with accelerated rates (μm/year) of ganglion cell + inner plexiform layer (–0.138 ± 0.053, p = 0.01; –0.158 ± 0.053, p = 0.003, respectively) and peripapillary retinal nerve fiber layer thinning (–0.305 ± 0.107, p = 0.004; –0.358 ± 0.106, p = 0.001, respectively).

Conclusion:

Ceramide levels are altered in PwMS and may be associated with retinal neurodegeneration and physical disability.

Keywords

Multiple sclerosis ceramides lipidomics

Get full access to this article

View all access options for this article.

References

Reich

Lucchinetti

Calabresi

PA.

Multiple sclerosis. N Engl J Med 2018; 378: 169–180.

Podbielska

Hogan

EL.

Molecular and immunogenic features of myelin lipids: Incitants or modulators of multiple sclerosis?

Mult Scler 2009; 15: 1011–1029.

Kurz

Parnham

Geisslinger

, et al. Ceramides as novel disease biomarkers. Trends Mol Med 2019; 25(1): 20–32.

Hannun

Obeid

LM.

Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9(2): 139–150.

Maceyka

Spiegel

Sphingolipid metabolites in inflammatory disease. Nature 2014; 510: 58–67.

Wheeler

Bandaru

VVR

Calabresi

, et al. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008; 131(Pt 11): 3092–3102.

van Doorn

Nijland

Dekker

, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 2012; 124(3): 397–410.

Checa

Khademi

Sar

, et al. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. Mult Scler 2015; 21(10): 1271–1279.

Kurz

Brunkhorst

Foerch

, et al. The relevance of ceramides and their synthesizing enzymes for multiple sclerosis. Clin Sci 2018; 132: 1963–1976.

10.

Vidaurre

Haines

Katz Sand

, et al. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 2014; 137(Pt 8): 2271–2286.

11.

Chaudhry

Cohen

Conway

DS.

Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14: 859–873.

12.

Barthelmes

de Bazo

Pewzner-Jung

, et al. Lack of ceramide synthase 2 suppresses the development of experimental autoimmune encephalomyelitis by impairing the migratory capacity of neutrophils. Brain Behav Immun 2015; 46: 280–292.

13.

Eberle

Ebel

Mayer

, et al. Exacerbation of experimental autoimmune encephalomyelitis in ceramide synthase 6 knockout mice is associated with enhanced activation/migration of neutrophils. Immunol Cell Biol 2015; 93(9): 825–836.

14.

Mayo

Trauger

Blain

, et al. Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. Nat Med 2014; 20(10): 1147–1156.

15.

Chao

Gutiérrez-Vázquez

Rothhammer

, et al. Metabolic control of astrocyte pathogenic activity via cPLA2-MAVS. Cell 2019; 179: 1483–1498.e22.

16.

Bhargava

Anthony

DC.

Metabolomics in multiple sclerosis disease course and progression. Mult Scler 2020; 26(5): 591–598.

17.

Lambe

Saidha

Bermel

RA.

Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials. Mult Scler 2020; 26(6): 624–639.

18.

Disanto

Barro

Benkert

, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017; 81: 857–870.

19.

Kuhle

Kropshofer

Haering

, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019; 92: e1007–e1015.

20.

Manouchehrinia

Westerlind

Kingwell

, et al. Age related multiple sclerosis severity score: Disability ranked by age. Mult Scler 2017; 23(14): 1938–1946.

21.

Filippatou

Shoemaker

Esch

, et al. Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell/inner plexiform layer thickness. Mult Scler 2019; 25(14): 1878–1887.

22.

Bhargava

Nogueras-Ortiz

Chawla

, et al. Altered levels of toll-like receptors in circulating extracellular vesicles in multiple sclerosis. Cells 2019; 8: 1058.

23.

Bligh

Dyer

WJ.

A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37(8): 911–917.

24.

Haughey

Cutler

Tamara

, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004; 55(2): 257–267.

25.

Mielke

Bandaru

VVR

Han

, et al. Factors affecting longitudinal trajectories of plasma sphingomyelins: The Baltimore Longitudinal Study of Aging. Aging Cell 2015; 14(1): 112–121.

26.

Castro

Ntranos

Amatruda

, et al. Body mass index in multiple sclerosis modulates ceramide-induced DNA methylation and disease course. EBioMedicine 2019; 43: 392–410.

27.

Pieragostino

Cicalini

Lanuti

, et al. Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients. Sci Rep 2018; 8: 3071.

28.

Bhargava

Nogueras-Ortiz

Kim

, et al. Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Mult Scler 2021; 27(4): 509–518.

29.

Wentling

Lopez-Gomez

Park

, et al. A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis. Brain 2019; 142: 2756–2774.

30.

Hobart

Freeman

Thompson

Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain 2000; 123(Pt 5): 1027–1040.

31.

Ratchford

Saidha

Sotirchos

, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013; 80: 47–54.

32.

Saidha

Al-Louzi

Ratchford

, et al. Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study. Ann Neurol 2015; 78(5): 801–813.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB

Serum ceramide levels are altered in multiple sclerosis

Abstract

Background:

Objectives:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material